EP0914422A4 - Mammalian genes involved in viral infection and tumor suppression - Google Patents

Mammalian genes involved in viral infection and tumor suppression

Info

Publication number
EP0914422A4
EP0914422A4 EP97918580A EP97918580A EP0914422A4 EP 0914422 A4 EP0914422 A4 EP 0914422A4 EP 97918580 A EP97918580 A EP 97918580A EP 97918580 A EP97918580 A EP 97918580A EP 0914422 A4 EP0914422 A4 EP 0914422A4
Authority
EP
European Patent Office
Prior art keywords
viral infection
genes involved
tumor suppression
mammalian genes
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP97918580A
Other languages
German (de)
French (fr)
Other versions
EP0914422A1 (en
EP0914422B1 (en
Inventor
Donald H Rubin
Edward L Organ
Raymond N Dubois
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanderbilt University
Original Assignee
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanderbilt University filed Critical Vanderbilt University
Publication of EP0914422A1 publication Critical patent/EP0914422A1/en
Publication of EP0914422A4 publication Critical patent/EP0914422A4/en
Application granted granted Critical
Publication of EP0914422B1 publication Critical patent/EP0914422B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1051—Gene trapping, e.g. exon-, intron-, IRES-, signal sequence-trap cloning, trap vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1079—Screening libraries by altering the phenotype or phenotypic trait of the host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1082—Preparation or screening gene libraries by chromosomal integration of polynucleotide sequences, HR-, site-specific-recombination, transposons, viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Abstract

The present invention provides methods of identifying cellular genes necessary for viral growth and cellular genes that function as tumor suppressors. Thus, the present invention provides nucleic acids related to and methods of reducing or preventing viral infection or cancer. The invention also provides methods of producing substantially virus-free cell cultures and methods for screening for additional such genes.
EP97918580A 1996-04-15 1997-04-11 Mammalian genes involved in viral infection Expired - Lifetime EP0914422B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1533496P 1996-04-15 1996-04-15
PCT/US1997/006067 WO1997039119A1 (en) 1996-04-15 1997-04-11 Mammalian genes involved in viral infection and tumor suppression
US15334 2001-12-11

Publications (3)

Publication Number Publication Date
EP0914422A1 EP0914422A1 (en) 1999-05-12
EP0914422A4 true EP0914422A4 (en) 2004-08-04
EP0914422B1 EP0914422B1 (en) 2009-11-18

Family

ID=21770820

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97918580A Expired - Lifetime EP0914422B1 (en) 1996-04-15 1997-04-11 Mammalian genes involved in viral infection

Country Status (8)

Country Link
US (4) US6448000B1 (en)
EP (1) EP0914422B1 (en)
JP (3) JP4106090B2 (en)
AT (1) ATE449172T1 (en)
AU (1) AU742243B2 (en)
CA (1) CA2251818A1 (en)
DE (1) DE69739658D1 (en)
WO (1) WO1997039119A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2251818A1 (en) 1996-04-15 1997-10-23 Vanderbilt University Mammalian genes involved in viral infection and tumor suppression
US6777177B1 (en) 1997-10-10 2004-08-17 Vanderbilt University Mammalian genes involved in viral infection and tumor suppression
AU9604198A (en) * 1997-10-10 1999-05-03 Vanderbilt University Mammalian genes involved in viral infection and tumor suppression
AU1582799A (en) 1997-11-07 1999-05-31 Iconix Pharmaceuticals, Inc. Surrogate genetics target characterization method
CN1173036C (en) * 1999-04-21 2004-10-27 卫生部艾滋病预防与控制中心 Whole-length gene sequence of donkey leucocytic hyptoxic vaccine strain for horse's infectious anemia (EIAV)
DE60237447D1 (en) * 2001-07-02 2010-10-07 Aimsco Ltd USE OF POLYCLONAL ANTI-HIV GOUGENES AS A THERAPEUTIC AGENT
CA2485092A1 (en) * 2002-05-02 2004-02-05 Vanderbilt University Mammalian genes involved in viral infection and tumor suppression
CA2506619A1 (en) * 2002-11-18 2004-08-19 Thomas W. Hodge Cell lines and host nucleic acid sequences related to infectious disease
JP2008520191A (en) 2004-10-27 2008-06-19 バンダービルト・ユニバーシティ Mammalian genes involved in infection
US20080176962A1 (en) * 2006-08-09 2008-07-24 Cohen Stanley N Methods and compositions for identifying cellular genes exploited by viral pathogens
US10202615B2 (en) 2010-12-10 2019-02-12 Vanderbilt University Mammalian genes involved in toxicity and infection

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993009230A1 (en) * 1991-11-05 1993-05-13 Board Of Regents, The University Of Texas System Cellular nucleic acid binding protein and uses thereof in regulating gene expression and in the treatment of aids
WO1994023041A2 (en) * 1993-04-02 1994-10-13 Ribogene, Inc. Method for selective inactivation of viral replication

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897355A (en) * 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
DK0458901T3 (en) 1989-02-14 1998-08-31 Massachusetts Inst Technology Inhibition of transformation of cells with elevated purine metabolic enzyme activity
US5364783A (en) 1990-05-14 1994-11-15 Massachusetts Institute Of Technology Retrovirus promoter-trap vectors
AU672969B2 (en) * 1992-03-10 1996-10-24 United States of America, as represented by The Secretary, Department of Health & Human Services, The Exchangeable template reaction
CA2251818A1 (en) 1996-04-15 1997-10-23 Vanderbilt University Mammalian genes involved in viral infection and tumor suppression
US6777177B1 (en) * 1997-10-10 2004-08-17 Vanderbilt University Mammalian genes involved in viral infection and tumor suppression

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993009230A1 (en) * 1991-11-05 1993-05-13 Board Of Regents, The University Of Texas System Cellular nucleic acid binding protein and uses thereof in regulating gene expression and in the treatment of aids
WO1994023041A2 (en) * 1993-04-02 1994-10-13 Ribogene, Inc. Method for selective inactivation of viral replication

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HICKS G.G. ET AL.: "Retrovirus gene traps", METHODS IN ENZYMOLOGY, vol. 254, 1995, United States, pages 263 - 275, XP008026976, ISSN: 0076-6879 *
LI L ET AL: "TSG101: A NOVEL TUMOR SUSCEPTIBILITY GENE ISOLATED BY CONTROLLED HOMOZYGOUS FUNCTIONAL KNOCKOUT OF ALLELIC LOCI IN MAMMALIAN CELLS", CELL, CELL PRESS, CAMBRIDGE, NA, US, vol. 85, 3 May 1996 (1996-05-03), pages 319 - 329, XP002934225, ISSN: 0092-8674 *
ORGAN E ET AL: "U3 gene-trap retrovirus selection of cellular mutants resistant to lytic reovirus infection", JOURNAL OF INVESTIGATIVE MEDICINE, vol. 3, no. 44, 3 May 1996 (1996-05-03), ISSN: 1081-5589, pages 320A, XP002090533 *

Also Published As

Publication number Publication date
AU4510597A (en) 1997-11-07
US6448000B1 (en) 2002-09-10
JP2008301825A (en) 2008-12-18
ATE449172T1 (en) 2009-12-15
AU742243B2 (en) 2001-12-20
DE69739658D1 (en) 2009-12-31
JP4106090B2 (en) 2008-06-25
US20030027198A1 (en) 2003-02-06
CA2251818A1 (en) 1997-10-23
EP0914422A1 (en) 1999-05-12
WO1997039119A1 (en) 1997-10-23
JP2001512302A (en) 2001-08-21
JP2008054685A (en) 2008-03-13
US20090092594A1 (en) 2009-04-09
US20050244817A1 (en) 2005-11-03
EP0914422B1 (en) 2009-11-18

Similar Documents

Publication Publication Date Title
MY125594A (en) Immortalized cell lines for virus growth
EA199801031A1 (en) PROTEINFARNESILTRANSFERASE INHIBITORS
AU7013401A (en) Methods for enhancing antibody-induced cell lysis and treating cancer
PL329922A1 (en) Quinoline carboxamides as inhibitors of the tumour necrosis factor and of phosphodiesterase
EP0914422A4 (en) Mammalian genes involved in viral infection and tumor suppression
EP0846160A4 (en) Methods for enhancing the production of viral vaccines in cell culture by interferon suppression
WO2001023592A3 (en) Methods for making recombinant proteins using apoptosis inhibitors
WO1994023041A3 (en) Method for selective inactivation of viral replication
MX9700789A (en) Dynemicin analogs.
PL331240A1 (en) Cut off soluble tumour necrosis factor receptors of i and ii type
CA2263713A1 (en) Lyophilization of cultured human cells to preserve rna and dna
AU6125296A (en) Oligonucleotides specific for hepatitis b virus
GR1002421B (en) Reproduction and transformation of cotton
WO2004010925A3 (en) Mammalian genes involved in viral infection and tumor suppression
MXPA01008137A (en) Antitumor antisense sequences directed against r1 and r2 components of ribonucleotide reductase.
AU4307197A (en) Herpesvirus saimiri as viral vector
WO1999019481A3 (en) Mammalian genes involved in viral infection and tumor suppression
BG105003A (en) Combinations of protein farnesyltransfer and hmg coa reductase inhibitors and their use to treat cancer
ZA200202413B (en) Cell-specific and/or tumor-specific promoter retargeting of herpes gamma 34.5 gene expression.
MY121698A (en) Method for immortalizing chicken cells.
ATE359372T1 (en) VECTORS FOR INHIBITING VIRAL AND TUMOR GROWTH
IL128546A0 (en) Cycloalkyl inhibitors of protein farnesyltransferase
PT925064E (en) 5-ANDROSTENO-3BETA, 17ALFA-DIOL AS AN INHIBITOR OF TUMOR GROWTH
AU2182801A (en) Method for producing adherent animal cells
AU4728299A (en) Antiproliferative and antiviral proteins and peptides

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19981113

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Ipc: 7G 01N 33/50 B

Ipc: 7C 12Q 1/68 B

Ipc: 7C 07K 14/47 B

Ipc: 7C 12N 15/10 B

Ipc: 7C 12N 15/11 B

Ipc: 7C 12N 15/12 A

A4 Supplementary search report drawn up and despatched

Effective date: 20040507

17Q First examination report despatched

Effective date: 20050202

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: VANDERBILT UNIVERSITY

17Q First examination report despatched

Effective date: 20050202

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RTI1 Title (correction)

Free format text: MAMMALIAN GENES INVOLVED IN VIRAL INFECTION

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 69739658

Country of ref document: DE

Date of ref document: 20091231

Kind code of ref document: P

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20091118

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091118

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100318

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091118

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091118

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091118

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091118

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091118

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20100819

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100219

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100430

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20100411

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20101230

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100411

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100430

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20101103

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091118

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100411

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100411